Cordis is a hearty subsidiary of Cardinal Health. The firm develops products to treat circulatory system diseases including congestive heart failure and cerebral aneurysms. Its Cordis Cardiology division focuses on cardiovascular disease diagnosis and treatment, while Cordis Endovascular develops devices for peripheral and biliary conditions. Biologics Delivery Systems makes cardiac mapping equipment used to improve the delivery of biological therapies. Cardinal Health acquired Cordis from Johnson & Johnson for $1.94 billion in 2015. (The sale did not include Cordis' former Biosense Webster unit, which develops medical sensor and electrophysiology technology for cardiovascular use.)